Pfizer bets on COVID-19 vaccine demand for years, sees sales of $26 bln in 2021

Pfizer Inc on Tuesday raised its forecast for 2021 COVID-19 vaccine sales by more than 70% to $26 billion and said demand from governments around the world trying to halt the pandemic could contribute to its growth for years to come.

Revenue from the vaccine - developed with German partner BioNTech SE - is expected to account for more than one third of Pfizer's full-year sales this year. The forecast is based on already signed contracts for 1.6 billion vaccine doses to be delivered this year. The company said it expects to sign more deals for this year and is in supply talks with several countries for 2022 and beyond.